{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:10:17Z","timestamp":1788765017189,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12015-026-11193-7","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:02:53Z","timestamp":1785736973000},"page":"3347-3359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural Killer Cell Immunotherapy After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia Patients: Phase I Clinical Trial"],"prefix":"10.1007","volume":"22","author":[{"given":"Shiva","family":"Eskandarian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Izadpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Parkhideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Mehdizade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Parkhideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhdeh","family":"Mohammadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrshad","family":"Seresht-Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Bakhtiyaridovvombaygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdollah","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Gharehbaghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Hajifathali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-4342","authenticated-orcid":false,"given":"Elham","family":"Roshandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"11193_CR1","doi-asserted-by":"crossref","unstructured":"Baragano Raneros, A., L\u00f3pez-Larrea, C., & Su\u00e1rez-\u00c1lvarez, B. (2019). Acute myeloid leukemia and NK cells: two warriors confront each other. Oncoimmunology, 8(2), e1539617","DOI":"10.1080\/2162402X.2018.1539617"},{"issue":"12","key":"11193_CR2","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","volume":"96","author":"G Nagel","year":"2017","unstructured":"Nagel, G., Weber, D., Fromm, E., Erhardt, S., L\u00fcbbert, M., Fiedler, W., German-Austrian, A. M. L., & Study Group (AMLSG). (2017). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Annals of hematology, 96(12), 1993\u20132003","journal-title":"Annals of hematology"},{"issue":"9","key":"11193_CR3","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.22233","volume":"107","author":"B Deschler","year":"2006","unstructured":"Deschler, B., & L\u00fcbbert, M. (2006). Acute myeloid leukemia: epidemiology and etiology. Cancer: Interdisciplinary International Journal of the American Cancer Society, 107(9), 2099\u20132107","journal-title":"Cancer: Interdisciplinary International Journal of the American Cancer Society"},{"key":"11193_CR4","doi-asserted-by":"crossref","unstructured":"Ranjbar, M., Barouni, M., Moazed, V., Fallahzadeh, H., & Sheikholeslami, S. (2020). Survival rate of patients with acute leukemia: a case study in Iran. Evidence Based Health Policy, Management and Economics","DOI":"10.18502\/jebhpme.v4i4.4888"},{"issue":"4","key":"11193_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020). Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discovery, 10(4), 506\u2013525","journal-title":"Cancer discovery"},{"key":"11193_CR6","doi-asserted-by":"crossref","unstructured":"Tsirigotis, P., Byrne, M., Schmid, C., Baron, F., Ciceri, F., Esteve, J., \u2026 Nagler,A. (2016). Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplantation, 51(11), 1431\u20131438","DOI":"10.1038\/bmt.2016.167"},{"key":"11193_CR7","doi-asserted-by":"publisher","first-page":"793274","DOI":"10.3389\/fonc.2021.793274","volume":"11","author":"I Abou Dalle","year":"2022","unstructured":"Abou Dalle, I., Atoui, A., & Bazarbachi, A. (2022). The elephant in the room: AML relapse post allogeneic hematopoietic cell transplantation. Frontiers in Oncology, 11, 793274","journal-title":"Frontiers in Oncology"},{"key":"11193_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.biopha.2017.10.100","volume":"97","author":"DO Acheampong","year":"2018","unstructured":"Acheampong, D. O., Adokoh, C. K., Asante, D. B., Asiamah, E. A., Barnie, P. A., Bonsu, D. O., & Kyei, F. (2018). Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomedicine & Pharmacotherapy, 97, 225\u2013232","journal-title":"Biomedicine & pharmacotherapy"},{"issue":"1","key":"11193_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","volume":"13","author":"J Xu","year":"2020","unstructured":"Xu, J., & Niu, T. (2020). Natural killer cell-based immunotherapy for acute myeloid leukemia. Journal of Hematology & Oncology, 13(1), 167","journal-title":"Journal of hematology & oncology"},{"issue":"4","key":"11193_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.beha.2016.10.010","volume":"29","author":"BC Shaffer","year":"2016","unstructured":"Shaffer, B. C., & Hsu, K. C. (2016). How important is NK alloreactivity and KIR in allogeneic transplantation? Best Practice & Research Clinical Haematology, 29(4), 351\u2013358","journal-title":"Best Practice & Research Clinical Haematology"},{"issue":"7","key":"11193_CR11","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/cells10071777","volume":"10","author":"J D\u0119bska-Zielkowska","year":"2021","unstructured":"D\u0119bska-Zielkowska, J., Moszkowska, G., Zieli\u0144ski, M., Zieli\u0144ska, H., Dukat-Mazurek, A., Trzonkowski, P., & Stefa\u0144ska, K. (2021). KIR receptors as key regulators of NK cells activity in health and disease. Cells, 10(7), 1777","journal-title":"Cells"},{"key":"11193_CR12","doi-asserted-by":"crossref","unstructured":"Arvindam, U. S., Aguilar, E. G., Felices, M., Murphy, W., & Miller, J. (2019). Natural killer cells in GvHD and GvL. Immune biology of Allogeneic Hematopoietic Stem Cell Transplantation (pp. 275\u2013292). Academic","DOI":"10.1016\/B978-0-12-812630-1.00016-5"},{"key":"11193_CR13","doi-asserted-by":"crossref","unstructured":"Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., Le, C. T.,\u2026 Weisdorf, D. J. (2009). Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood, The Journal of the American Society of Hematology, 113(3), 726\u2013732","DOI":"10.1182\/blood-2008-07-171926"},{"issue":"2","key":"11193_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A., & Miller, J. S. (2021). Exploring the NK cell platform for cancer immunotherapy. Nature reviews Clinical oncology, 18(2), 85\u2013100","journal-title":"Nature reviews Clinical oncology"},{"issue":"3","key":"11193_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12185-018-2407-5","volume":"107","author":"RS Mehta","year":"2018","unstructured":"Mehta, R. S., Randolph, B., Daher, M., & Rezvani, K. (2018). NK cell therapy for hematologic malignancies. International journal of hematology, 107(3), 262\u2013270","journal-title":"International journal of hematology"},{"key":"11193_CR16","doi-asserted-by":"crossref","unstructured":"Silla, L., Valim, V., Pezzi, A., da Silva, M., Wilke, I., Nobrega, J., \u2026 Lee, D. A. (2021). Adoptive immunotherapy with double-bright (CD56bright\/CD16bright) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia:a proof\u2010of\u2010concept study. British Journal of Haematology, 195(5), 710\u2013721","DOI":"10.1111\/bjh.17751"},{"key":"11193_CR17","doi-asserted-by":"crossref","unstructured":"Kim, S. A., Koh, Y., Jung, M., Hwang, Y. K., Byun, J. M., Hong, J., \u2026 Yoon, S. S.(2021). A Pilot Study of MG4101, Allogeneic Natural Killer Cell, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 138, 3835","DOI":"10.1182\/blood-2021-152137"},{"key":"11193_CR18","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rklund, A. T., Carlsten, M., Sohlberg, E., Liu, L. L., Clancy, T., Karimi, M.,\u2026 Malmberg, K. J. (2018). Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Clinical Cancer Research, 24(8), 1834\u20131844","DOI":"10.1158\/1078-0432.CCR-17-3196"},{"key":"11193_CR19","doi-asserted-by":"crossref","unstructured":"Stern, M., Passweg, J. R., Meyer-Monard, S., Esser, R., Tonn, T., Soerensen, J., \u2026Koehl, U. (2013). Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplantation, 48(3), 433\u2013438","DOI":"10.1038\/bmt.2012.162"},{"key":"11193_CR20","doi-asserted-by":"crossref","unstructured":"Choi, I., Yoon, S. R., Park, S. Y., Kim, H., Jung, S. J., Jang, Y. J., \u2026 Lee, K. H.(2014). Donor-derived natural killer cells infused after human leukocyte antigen\u2013haploidentical hematopoietic cell transplantation: a dose-escalation study. Biology of Blood and Marrow Transplantation, 20(5), 696\u2013704","DOI":"10.1016\/j.bbmt.2014.01.031"},{"key":"11193_CR21","doi-asserted-by":"crossref","unstructured":"Lee, D. A., Denman, C. J., Rondon, G., Woodworth, G., Chen, J., Fisher, T., \u2026 Champlin, R. E. (2016). Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial. Biology of Blood and Marrow Transplantation, 22(7), 1290\u20131298","DOI":"10.1016\/j.bbmt.2016.04.009"},{"key":"11193_CR22","doi-asserted-by":"crossref","unstructured":"Curti, A., Ruggeri, L., Parisi, S., Bontadini, A., Dan, E., Motta, M. R., \u2026 Lemoli,R. M. (2016). Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clinical Cancer Research, 22(8), 1914\u20131921","DOI":"10.1158\/1078-0432.CCR-15-1604"},{"key":"11193_CR23","doi-asserted-by":"crossref","unstructured":"Schmid, H., Schneidawind, C., Jahnke, S., Kettemann, F., Secker, K. A., Duerr-Stoerzer,S., \u2026 Schneidawind, D. (2018). Culture-expanded human invariant natural killer T cells suppress T-cell alloreactivity and eradicate leukemia. Frontiers in Immunology, 9, 1817","DOI":"10.3389\/fimmu.2018.01817"},{"issue":"7","key":"11193_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2183\/pjab.91.292","volume":"91","author":"M Taniguchi","year":"2015","unstructured":"Taniguchi, M., Harada, M., Dashtsoodol, N., & Kojo, S. (2015). Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy. Proceedings of the Japan Academy Series B, 91(7), 292\u2013304","journal-title":"Proceedings of the Japan Academy Series B"},{"issue":"18","key":"11193_CR25","first-page":"3116","volume":"122","author":"D Schneidawind","year":"2013","unstructured":"Schneidawind, D., Pierini, A., & Negrin, R. S. (2013). Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. Blood The Journal of the American Society of Hematology, 122(18), 3116\u20133121","journal-title":"Blood The Journal of the American Society of Hematology"},{"issue":"4","key":"11193_CR26","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/cancers12040817","volume":"12","author":"K Shimizu","year":"2020","unstructured":"Shimizu, K., Iyoda, T., Yamasaki, S., Kadowaki, N., Tojo, A., & Fujii, S. I. (2020). NK and NKT cell-mediated immune surveillance against hematological malignancies. Cancers, 12(4), 817","journal-title":"Cancers"},{"key":"11193_CR27","doi-asserted-by":"crossref","unstructured":"Rubio-Azpeitia, E., P\u00e9rez\u2010Corral, A. M., Dorado\u2010Herrero, N., Monsalvo, S., P\u00e9rez\u2010Balsera,G., Fern\u00e1ndez\u2010Santos, M. E., \u2026 Anguita, J. (2022). Clinical grade production of IL\u201015 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post\u2010transplant cyclophosphamide. Transfusion, 62(2), 374\u2013385","DOI":"10.1111\/trf.16790"},{"key":"11193_CR28","doi-asserted-by":"crossref","unstructured":"Van Ostaijen-Ten Dam, M. M., Prins, H. J., Boerman, G. H., Vervat, C., Pende, D.,Putter, H., \u2026 Schilham, M. W. (2016). Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential. Journal of Immunotherapy, 39(2), 90\u2013100","DOI":"10.1097\/CJI.0000000000000110"},{"key":"11193_CR29","doi-asserted-by":"crossref","unstructured":"Jaiswal, S. R., Zaman, S., Nedunchezhian, M., Chakrabarti, A., Bhakuni, P., Ahmed,M., \u2026 Chakrabarti, S. (2017). CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: a pilot study. Cytotherapy, 19(4), 531\u2013542","DOI":"10.1016\/j.jcyt.2016.12.006"},{"issue":"1","key":"11193_CR30","first-page":"56","volume":"2013","author":"K van Besien","year":"2013","unstructured":"van Besien, K. (2013). Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology 2013 the American Society of Hematology Education Program Book, 2013(1), 56\u201362","journal-title":"Hematology 2013 the American Society of Hematology Education Program Book"},{"key":"11193_CR31","doi-asserted-by":"crossref","unstructured":"Nguyen, R., Wu, H., Pounds, S., Inaba, H., Ribeiro, R. C., Cullins, D., \u2026 Rubnitz,J. E. (2019). A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. Journal for Immuno Therapy of Cancer, 7(1), 81","DOI":"10.1186\/s40425-019-0564-6"},{"key":"11193_CR32","doi-asserted-by":"crossref","unstructured":"Mushtaq, M. U., Shahzad, M., Shah, A. Y., Chaudhary, S. G., Zafar, M. U., Anwar, I.,\u2026 McGuirk, J. P. (2022). Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Frontiers in Immunology, 13, 1005031","DOI":"10.3389\/fimmu.2022.1005031"},{"key":"11193_CR33","doi-asserted-by":"crossref","unstructured":"Song, Y., Hu, B., Liu, Y., Jin, Z., Zhang, Y., Lin, D., \u2026 Liu, H. (2018). IL-12\/IL\u201018\u2010preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation. European Journal of Immunology, 48(4), 670\u2013682","DOI":"10.1002\/eji.201747177"},{"key":"11193_CR34","doi-asserted-by":"crossref","unstructured":"Ciurea, S. O., Kongtim, P., Soebbing, D., Trikha, P., Behbehani, G., Rondon, G., \u2026Champlin, R. E. (2022). Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia, 36(1), 155\u2013164","DOI":"10.1038\/s41375-021-01349-4"},{"key":"11193_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","volume":"7","author":"J Ogonek","year":"2016","unstructured":"Ogonek, J., Kralj Juric, M., Ghimire, S., Varanasi, P. R., Holler, E., Greinix, H., & Weissinger, E. (2016). Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Frontiers in immunology, 7, 507","journal-title":"Frontiers in immunology"},{"key":"11193_CR36","doi-asserted-by":"crossref","unstructured":"Singh, M., D\u2019Silva, S. Z., & Saxena, A. (2019). Assessment of immune reconstitution following hematopoietic stem cell transplantation. Cells of the Immune System","DOI":"10.5772\/intechopen.89198"},{"issue":"4","key":"11193_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh, M., Mansilla-Soto, J., Rivi\u00e8re, I., & Sadelain, M. (2023). Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discovery, 13(4), 829\u2013843","journal-title":"Cancer Discovery"},{"key":"11193_CR38","doi-asserted-by":"crossref","unstructured":"Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe,T., \u2026 Fehniger, T. A. (2016). Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine, 8(357), 357ra123-357ra123","DOI":"10.1126\/scitranslmed.aaf2341"},{"key":"11193_CR39","doi-asserted-by":"crossref","unstructured":"Rubnitz, J. E., Inaba, H., Kang, G., Gan, K., Hartford, C., Triplett, B. M., \u2026 Leung,W. (2015). Natural killer cell therapy in children with relapsed leukemia. Pediatric Blood & Cancer, 62(8), 1468\u20131472","DOI":"10.1002\/pbc.25555"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11193-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11193-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11193-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:59:32Z","timestamp":1788764372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11193-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11193"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11193-7","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This phase I\/II open-labeled clinical trial was registered at the Iranian Registry of Clinical Trials (IRCT20230801058996N2) and approved by the ethics committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.REC.1402.006).","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants (patients and donors) signed a written informed consent form before enrollment in the study.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}